ALUPENT
LOE ApproachingNDAORALTABLETPriority Review
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral tablet small-molecule medication approved in 1974 by Boehringer Ingelheim. The specific indication and mechanism of action are not currently documented in available data. This is a legacy NDA product with approaching loss of exclusivity.
LOE Approaching
Moderate competitive pressure (30% intensity) suggests declining market opportunity; expect reduced team investment as exclusivity window closes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring momentum for ALUPENT. Working on this product offers stability in a mature market but limited growth trajectory and team expansion opportunities.
Brand ManagerField Sales
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.